Arcus Biosciences, Inc. · NYSE:RCUS

Arcus Biosciences — Q4 2023 Earnings Presentation

63 slides from Arcus Biosciences's earnings presentation, Feb 21, 2024

  1. Slide 1: Combining to Cure

    ® COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. CORPORATE PRESENTATION February 21, 2024

  2. Slide 2: Forward-looking Statements/Safe Harbor

    Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. (“we,” “Arcus” or the “Company”) made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results

  3. Slide 3: Late-stage Portfolio of Differentiated Assets, Productive R&D Engine

    Arcus Has Created a Late-stage Portfolio of Differentiated Assets, Fueled by a Highly Productive R&D Engine FUNDING INTO LATE-STAGE COMPANY MULTIPLE PHASE 3 2027 STUDIES FOR DOM IN Line of sight to first ~$1.2B in pro forma cash, product approval (dom/zim) LUNG & UPPER GI in 2024 cash equivalents &

  4. Slide 4: Broad Portfolio of Investigational Molecules Targeting Huge Market Opportunities

    Arcus Has a Broad Portfolio of Investigational Molecules with Best- in-Class Potential Targeting Huge Market Opportunities DIFFERENTIATED ANTI-TIGIT + DIFFERENTIATED SMALL MOLECULES NEXT-GENERATION PROGRAMS ANTI-PD-1 BACKBONE casdatifan: Potential best-in-class HIF- AB801: Potential best-in-class do

  5. Slide 5: Three Late-Stage Programs with Multiple Upcoming Milestones

    Three Late-Stage Programs with Multiple Upcoming Milestones; Earlier-Stage Portfolio Maturing Program Disease Study Line & Regimen Ph 1/1b Ph 2 Ph 3 Upcoming Milestones 1L, PD-L1 all-comers, metastatic • 2024: Enrollment completion dom + zim + chemo vs pembro + chemo Perioperative lung cancer PLANNE

  6. Slide 6: Our Partnerships Expand & Accelerate Opportunities

    Our Partnerships Greatly Expand & Accelerate Opportunities Inherent in Arcus’s Portfolio 10-YEAR COLLABORATION • Gilead has opted into 5 molecules to date -- shares costs for studies within the joint development plan • Arcus retains U.S. co-commercial rights COLLABORATION FOR JAPAN AND OTHER TERRITO

  7. Slide 7: Domvanalimab in NSCLC and Upper GI Cancers

    Domvanalimab in Non-Small Cell Lung Cancer and Upper GI Cancers 7 © Arcus Biosciences 2024

  8. Slide 8: Domvanalimab, an Fc-Silent anti-TIGIT

    Domvanalimab, an Fc-Silent anti-TIGIT Dom may have important DOMVANALIMAB differences over Fc-enabled Most clinically advanced Fc-silent anti-TIGIT antibody in development anti-TIGIT competitors ✓ Peripheral Treg numbers do not ZIMBERELIMAB decrease with dom + zim, but they do Anti-PD-1 antibody; ap

  9. Slide 9: Two De-Risking Phase 2 Datasets for Dom Plus Zim Regimens

    Two De-Risking Phase 2 Datasets for Domvanalimab Plus Zimberelimab Regimens Were Presented in 2023 1L Gastric/EAC/GEJ 1L PD-L1 high NSCLC dom + zim + FOLFOX (n=40) dom + zim vs. zim vs. etruma + dom + zim (n=150) • PD-L1-high (TAP ≥5%) for DZ + FOLFOX*: • PFS HRs: − ORR/cORR: 80% / 73% − 0.67 for DZ

  10. Slide 10: Phase 3 Program Targeting Significant Market Opportunities

    Phase 3 Program for Dom-Based Combinations is Targeting Significant Market Opportunities STUDY LEAD SPONSOR SETTING US PATIENT POPULATION1 1L NSCLC, PD-L1 All comers 119k patients Perioperative lung cancer TBA Stage 3 NSCLC 21k patients 1L Gastric/GEJ/EAC 25k patients $10B+ addressable Multi-billion

  11. Slide 11: Summary of EDGE-Gastric Arm-A1 Results

    Summary of EDGE-Gastric Arm-A1 Results and Domvanalimab Plus Zimberelimab Clinical Program in Upper GI Cancers Data presented at the November 2023 ASCO Plenary Series, based on data cut off of September 4, 2023. 11 © Arcus Biosciences 2024

  12. Slide 12: Phase 2 Trial of Dom and Zim in Advanced Upper GI Malignancies

    Phase 2 Trial to Evaluate Dom and Zim Combinations in Advanced Upper GI Malignancies ARMS NOT RANDOMIZED, ENROLLED SEQUENTIALLY ARM A1: COHORT A dom + zim Q4W + FOLFOX Q2W 1L N ≈ 40 per arm ARM A2: zim Q4W + FOLFOX Q2W KEY ELIGIBILITY CRITERIA PRIMARY ENDPOINTS: • Locally advanced • Safety unresecta

  13. Slide 13: Arm A1 Results Presented at ASCO Plenary

    Results for Arm A1 in 1L Metastatic Gastric/GEJ/EAC Were Presented at ASCO Plenary in November 2023 KEY ELIGIBILITY CRITERIA • First-line locally advanced PRIMARY ENDPOINTS: unresectable or metastatic gastric/GEJ/EAC • Safety • Investigator ORR • Measurable disease per dom 1600 mg Q4W N ≈ 40 RECIST

  14. Slide 14: Encouraging ORR and 6-Month PFS Results

    Encouraging ORR and 6-Month PFS Results • As of the 4 September 2023 data cutoff, 24 patients (59%) continued on study treatment PD-L1 High* PD-L1 Low* Efficacy-Evaluable (TAP ≥5%) (TAP <5%) N=41 N=15 N=24 n (%) n (%) n (%) ORR, % [95% CI] 80 [52, 96] 46 [26, 67] 59 [42, 74] Confirmed ORR, % [95% CI

  15. Slide 15: Almost All Patients Experience Some Benefit Irrespective of PD-L1

    Almost All Patients Experience Some Benefit, Irrespective of PD-L1 Status * *MSI-high TAP: tumor area positiv ity 15 Janjigian et al. ASCO Plenary Series, Nov . 7, 2023; data cut of f of Sept. 4, 2023 © Arcus Biosciences 2024

  16. Slide 16: Landmark 6-Month PFS Compares Favorably to Benchmark

    Landmark 6-Month PFS Compares Favorably to Benchmark Data of 60-65%; Median PFS Still Immature Efficacy-Evaluable (N=41) PD-L1 High (TAP ≥5%, N=15) 6-month PFS = 77% 6-month PFS = 93% Median, months Month 6 Rate, % Median Follow-up Median, months Month 6 Rate, % Median Follow-up Events, n (%) Events

  17. Slide 17: Safety Profile for Dom + Zim + FOLFOX Similar to FOLFOX Alone

    Safety Profile for Dom + Zim + FOLFOX is Similar to that of FOLFOX Alone Arm A1 TEAE N=41, n (% ) 70 Any Grade TEAEs ≥20% Any TEAE 41 (100) Grade 1-2 60 Grade ≥3 TEAEs related to any study 40 (98) drug 50 Grade ≥3 TEAEs 28 (68) Patients, % 40 Grade ≥3 TEAEs related to any 49 23 (56) study drug 30 54

  18. Slide 18: Phase 3 Dom + Zim + Chemo vs Nivo + Chemo in 1L Gastric

    Phase 3 Evaluating Dom + Zim + Chemo vs Nivo + Chemo in 1L Gastric, GEJ and Esophageal Adenocarcinoma KEY ELIGIBILITY N=970 CRITERIA: • 1L locally advanced DUAL PRIMARY ENDPOINTS: unresectable or domvanalimab + zimberelimab + PI • OS ITT metastatic w/o prior choice of chemo* • OS in TAP ≥5% systemic

  19. Slide 19: Summary of ARC-7 Results in NSCLC

    Summary of ARC-7 Results and Domvanalimab Plus Zimberelimab Clinical Program in Non-Small Cell Lung Cancer Data presented at the 2023 ASCO Annual Meeting, based on data cut-off of Feb. 7, 2023. 19 © Arcus Biosciences 2024

  20. Slide 20: Randomized Ph2 Study in 1L PD-L1-High NSCLC

    Randomized, Open-label, Ph2 Study in First-Line, Metastatic, PD-L1-High NSCLC ARM 1 STAGE IV NSCLC zim (Z) 360 mg IV Q3W KEY ELIGIBILITY: CO-PRIMARY ENDPOINTS • Treatment-naïve for • Investigator-assessed ORR & metastatic disease ARM 2 PFS per RECIST v1.1 R dom + zim (DZ) • PD-L1 ≥50%, locally 1:1:1

  21. Slide 21: Dom-containing Arms Improved ORRs vs Zim Monotherapy

    Dom-containing Arms Improved ORRs vs Zim Monotherapy • Across all arms, one patient in the DZ arm had a pending partial response that was confirmed after data cut-off date • Subjects ongoing treatment with stable disease have potential to contribute to objective response rate with further data matur

  22. Slide 22: Addition of Dom to Zim Reduced Risk of Progression by 33%

    Addition of Dom to Zim Resulted in a 33% Reduction in Risk of Progression or Death, Compared to Zim Monotherapy CI: conf idence interv al; D/dom: domv analimab; HR: hazard ratio; NE: not ev aluable; PFS: progression- f ree surv iv al; Z/zim: zimberelimab 22 Johnson et al. Abstract 397600, ASCO 2023;

  23. Slide 23: Overall Safety Profile

    Overall Safety Profile ARM 1 (Z) ARM 2 (DZ) ARM 3 (EDZ) ITT, % (n) (n=50) (n=50) (n=50) Any TEAEs 100% (50) 98% (49) 98% (49) Grade ≥3 TEAE 64% (32) 46% (23) 60% (30) Grade 5, Related to Study Treatment* 2% (1) 2% (1) 4% (2) Serious TEAE 56% (28) 34% (17) 52% (26) TEAEs leading to study drug 28% (14

  24. Slide 24: Phase 3 Dom + Zim + Chemo vs Pembro + Chemo in 1L NSCLC

    Phase 3 Evaluating Dom + Zim + Chemo vs. Pembro + Chemo in 1L NSCLC (All PD-L1 Subgroups) • Uses standard of care, pembrolizumab, in the comparator arm ELIGIBILITY CRITERIA: ARM A ENDPOINTS: • Metastatic NSCLC without dom + zim + platinum doublet PRIMARY actionable mutations (ARM A vs B) • No prior

  25. Slide 25: Phase 3 Dom + Durva vs Placebo + Durva in Stage III NSCLC

    Phase 3 Evaluating Dom + Durva vs Placebo + Durva in Unresectable, Stage III NSCLC • Combines domvanalimab (dom) with durvalumab (durva) standard-of-care in Stage III NSCLC • Potential to be first anti-TIGIT combination in this curative intent setting PATIENT POPULATION: ARM A (N=430) • Patients wit

  26. Slide 26: HIF-2α Program

    HIF-2α Program 26 © Arcus Biosciences 2024

  27. Slide 27: Value Proposition for Casdatifan (AB521)

    Value Proposition for Casdatifan (AB521), a Potential Best- in-Class HIF-2α Inhibitor Efficacy Novel Combinations Opportunity to reach greater intra- Opportunity to create potentially best- tumoral HIF-2α inhibition compared in-class and first-in-class to 120 mg dose of belzutifan combinations • Req

  28. Slide 28: Preclinical Characterization Confirms Greater Potency of Casdatifan vs Belzutifan

    Extensive Preclinical Characterization Confirms Greater Potency of Casdatifan (AB521) Relative to that of Belzutifan ASSAY Casdatifan Belzutifana HIF-2α 786-O Luc Reporter 8.2 ± 2.5 (n=24) 16.9 ± 10.1 (n=8) IC50 (nM) CELLULAR Control 786-O Luc Reporter > 10,000 (n=6) > 10,000 (n=7) IC50 (nM) HIF-2α

  29. Slide 29: Casdatifan Monotherapy Dose Escalation/Expansion in ccRCC

    Casdatifan (AB521) Monotherapy Dose Escalation/ Expansion in ccRCC is Ongoing PH 1 DOSE ESCALATION EXPANSION COHORTS (2L+ ccRCC) 3+3 design with 21-day DLT window Solid-tumor patients w/o SOC KEY INCLUSION CRITERIA 100mg (n=30) • At least 1 measurable lesion per COMPLETED ENROLLMENT Flexible RECIST

  30. Slide 30: Casdatifan 20mg Achieves Similar PD Effect as Belzutifan 120mg

    Casdatifan (AB521) 20mg Achieves Similar PD Effect as belzutifan at 120mg 20 mg of cas achieves near-complete suppression of HIF- Human PK profile of cas increases in a dose-linear 2α-dependent EPO (peripheral PD marker) fashion A 120mg dose of belzutifan (the approved dose) is Daily 100mg cas dose

  31. Slide 31: Casdatifan Shows Dose-Linear Exposure Increase up to 100mg

    Casdatifan Shows Dose-Linear Exposure Increase up to 100mg • Belzutifan steady state AUC only increased 30% between 120 and 240 mg QD, which may limit its ability to maximize target engagement Belzutifan Daily Dose Casdatifan Daily Dose 120 mg 240 mg 20 mg 100 mg (n=58) (n=7) (n=3) (n=24) Steady-sta

  32. Slide 32: Hemoglobin Changes After Casdatifan 100 mg Similar to Belzutifan

    Hemoglobin Changes After Casdatifan (AB521) 100 mg Administration are Similar to that of Belzutifan at 120 mg Hemoglobin level (mean±SD) [g/dL] Cas, 50 mg daily (N≤15) Belz 120 mg daily, Male (N=29) Cas, 100 mg daily (N≤32) Belz 120 mg daily, Female (N=19) Hemoglobin change from baseline (mean±SD) [

  33. Slide 33: Treatment-Emergent Adverse Events

    Treatment-Emergent Adverse Events (as of Dec. 15, 2023) To date, rates of adverse events, including anemia and hypoxia, appear consistent with observations from historical trials of belzutifan. TEAEs Reported in ≥2 Patients Grade ≥3 TEAEs Dose Escalation Cohorts Dose Escalation Cohorts Preferred Ter

  34. Slide 34: Early Efficacy Signals in ccRCC Patients

    Early Efficacy Signals in ccRCC Patients Dose Escalation (n=4) Dose Expansion 100mg Cohort (n=30) • Meaningful clinical activity observed in 3 of the • Completed enrollment in Nov. 2023 4 very advanced ccRCC patients • Majority of patients have had one or 2 scans, − 2 ccRCC patients, one still on tr

  35. Slide 35: Phase 1b/2 Study of AB521 + Zanzalintinib +/- Nivolumab

    Phase 1b/2 Study of AB521 + Zanzalintinib +/- Nivolumab in Advanced Solid Tumors Including ccRCC* DOSE FINDING DOSE EXPANSION * Potential multiple additional cohorts of ~6 patients each, guided by BOIN DLT rules Zanza + AB521 RD+1 COHORT A Zanza 100 mg COHORT 1 Zanza RD + STELLAR-009 KEY STUDY OBJEC

  36. Slide 36: CD73-Adenosine Axis Programs

    CD73-Adenosine Axis Programs 36 © Arcus Biosciences 2024

  37. Slide 37: Quemliclustat in Pancreatic Cancer

    Quemliclustat in Pancreatic Cancer 37 © Arcus Biosciences 2024

  38. Slide 38: Quemliclustat: Unique, Highly Potent Selective CD73 Inhibitor

    Quemliclustat (quemli): A Unique, Highly Potent and Selective Small Molecule CD73 Inhibitor with Several Key Advantages QUEMLICLUSTAT • Highly potent molecule Potential advantages over • Target coverage achieved at doses CD73 antibodies1 as low as 25 mg every two weeks • Extremely long (4+ days) hal

  39. Slide 39: Final OS Analysis for Quemliclustat and Zimberelimab (ARC-8)

    Final Overall Survival Analysis for Quemliclustat and Zimberelimab in Pancreatic Cancer (ARC-8) Data presented at ASCO GI, January 19, 2024, based on a data cutoff of June 19, 2023. 39 © Arcus Biosciences 2024

  40. Slide 40: Highlights from the ARC-8 Study in 1L PDAC

    Highlights from the ARC-8 Study in 1L PDAC Median overall survival (mOS) was 15.7 months for patients treated with a quemliclustat- based regimen, which exceeds the historical benchmark data for chemotherapy alone (8.5 – 11.7 months)1,2 A 37% reduction in risk of death and a 5.9-month improvement in

  41. Slide 41: ARC-8 Study Design

    ARC-8 Study Design Included Dose Escalation, Expansion and Randomized Portions RANDOMIZATION DOSE ESCALATION DOSE EXPANSION (WITH AND WITHOUT ZIM) 125 mg quemli IV Q2W + G/nP + zim (n=3-6) COHORT A1 100 mg QZ + G/nP (n=61) COHORT A 100 mg quemli IV Q2W R 1L mPDAC + G/nP + zim (n=6) RDE 100 mg QZ + G

  42. Slide 42: Dataset Includes Four Groups of Patients Treated with 100 mg Quemli

    Dataset Includes Four Groups of Patients Treated with 100 mg of Quemli Quemli Cohort Combination Participants Dosed >18m OS f/u? Population Dose Dose escalation 25 mg Q + Z + G/nP (quad) 4 Yes 1L mPDAC Dose escalation 50 mg Q + Z + G/nP (quad) 6 Yes 1L mPDAC Dose escalation 75 mg Q + Z + G/nP (quad)

  43. Slide 43: Demographics and Baseline Characteristics Well Balanced

    Demographics And Baseline Characteristics Are Well Balanced Across Arms & Efficacy-evaluated Populations % ECOG 1 (65%-69%) Was Higher than Historical G/nP Studies (42-57%); % Liver Mets (59%-69%) Was Slightly Lower than Historical G/nP Studies (78-85%) A2: Q + G/nP A1: QZ + G/nP Pooled Q100 QZ + G/

  44. Slide 44: 21-month Median Follow-up, OS Exceeds Ph3 Benchmarks for G/nP

    With 21-month Median Follow-up, OS Results Exceed Ph3 Benchmarks for G/nP Phase 3 G/nP median OS G/nP Benchmarks1,2 Benchmark Median OS 8.5 – 11.1 months CI: conf idence interv al; G/nP: gemcitabine/nab-paclitaxel; Ph3: Phase 3 1. Abraxane USPI, 2020 and Wainberg ZA, Melisi D, Macarulla T, et al. NA

  45. Slide 45: Favorable OS With & Without Liver Metastasis

    Favorable OS for Patients With & Without Liver Metastasis • Because ARC-8 had a lower incidence of liver mets than historical studies, we analyzed the OS for ARC-8 patients with and without liver mets as shown below • When adjusting for the lower incidence of liver mets in the triplet arm, mOS for t

  46. Slide 46: Safety Profile Similar to G/nP

    Safety Profile Similar to G/nP with Regards to Overall TEAEs NAPOLI-3 G/nP A2: Q + G/nP Pooled Q100 QZ + G/nP All Pooled Q100 Q % Benchmark4 (n=29) (n=93) (±Z)+G/nP (n=122) (n=379) Any TEAE 100 100 100 99 Any TRAE 100 98.9 99.2 93 Grade 3-5 TEAE 89.7 83.9 85.2 86 Grade 3-5 TRAE 75.9 72.0 73.0 68 Ser

  47. Slide 47: Arcus & Medidata AI Synthetic Control Arm Project

    Arcus & Medidata AI Synthetic Control Arm (SCA) Project • Developed in collaboration with Medidata, the industry’s leading provider of electronic data capture for clinical trials • Constructed SCA using historical data from patients treated with G/nP alone and balanced to the patient baseline charac

  48. Slide 48: Quemli-based Regimen Reduced Risk of Death by 37%

    Quemli-based Regimen Significantly Reduced Risk of Death by 37% and increased mOS by 5.9 months Compared to SCA CI: conf idence interv al; mOS: median ov erall surv iv al; quemli: quemliclustat; SCA: Sy nthetic Control Arm 48 Wainberg ZA, et al. ASCO GI, Jan. 19, 2024, data cut of f of June 19, 2023

  49. Slide 49: Etrumadenant in Colorectal Cancer

    Etrumadenant in Colorectal Cancer 49 © Arcus Biosciences 2024

  50. Slide 50: Etrumadenant: Potentially Best-in-Class Adenosine Receptor Antagonist

    Etrumadenant Represents a Potentially Best-in-Class Adenosine Receptor Antagonist ETRUMADENANT Etruma has ideal • Highly potent small molecule that pharmacological properties inhibits both the A2aR and A2bR receptors ✓ Retains potency in physiologically • Excellent penetration of tumor tissue releva

  51. Slide 51: Randomized Phase 2 Study of Etruma Plus Zim in 3L+ mCRC

    Randomized Phase 2 Study to Evaluate Etruma Plus Zim- Based Combinations in 3L+ mCRC • Randomized Phase 2 study evaluating etruma + zim + chemo combinations vs. SOC in 2L/3L mCRC • Mature PFS / OS data for Cohort B (3L; n=105) expected to be presented in 1H24 • Cohort A (2L) results are still immatu

  52. Slide 52: AXL Program

    AXL Program 52 © Arcus Biosciences 2024

  53. Slide 53: AXL Signaling a Common Mechanism of Resistance

    AXL Signaling is a Common Mechanism of Resistance to Chemotherapy and Immunotherapy in Tumors AXL signals via Ligand-dependent and Ligand-independent mechanisms THERAPEUTIC HYPOTHESIS: AXL inhibition will overcome multiple mechanisms of drug-resistance MERTK EGFR TYRO3 VEGFR HER2 AB801 sensitizes ca

  54. Slide 54: AB801 Potent, Selective, Efficacious AXL Inhibitor

    AB801 is a Potent, Selective, and Efficacious AXL Inhibitor Combination of AB801 with Oxaliplatin & α-PD-1 AB801 is a highly potent Increases Anti-Tumor Efficacy and Survival and selective AXL inhibitor in Preclinical Models* Assay AB801 AXL Ki 0.024 nM 3000 Oxaliplatin Stopped 100 Stopped Treatment

  55. Slide 55: AB801 Believed Most Potent & Selective AXL Inhibitor in Clinic

    AB801 is Believed to be the Most Potent & Selective AXL Inhibitor in Clinical Development THERAPEUTIC HYPOTHESIS: Inhibiting AXL will overcome resistance against chemotherapy and immunotherapy in human tumors • AB801 was designed to potently and selectively inhibit AXL signaling in tumors, resulting

  56. Slide 56: Appendix

    APPENDIX 56 © Arcus Biosciences 2024

  57. Slide 57: Diverse Pipeline with Multiple Molecules in Late-Stage Development

    Diverse Pipeline with Multiple Molecules in Late-Stage Development MOLECULE INDICATION STUDY PHASE 1 PHASE 1B PHASE 2 PHASE 3 STAR-131; Perioperative lung cancer dom + zim + chemo → dom + zim in planning Stage III, unresectable, PD-L1≥1% NSCLC dom + durvalumab vs durvalumab DOMVANALIMAB (DOM) 1L NSC

  58. Slide 58: Domvanalimab: Most Clinically Advanced Fc-Silent TIGIT Antibody

    Domvanalimab (dom): Most Clinically Advanced Fc-Silent TIGIT Antibody in Clinical Development IMMUNOSUPPRESSION IMMUNE CELL ACTIVATION & TUMOR CELL KILLING T or NK cell T or NK cell PD-1 TIGIT TIGIT Zimberelimab PD-1 CD226 Cytotoxic CD226 proteins PD-L1 released CD155 domvanalimab PD-L1 CD155 Tumor

  59. Slide 59: HIF-2α Regulates Multiple Facets of Cancer Cell Biology

    HIF-2α Regulates Multiple Facets of Cancer Cell Biology SDH: Succinate dehy drogenase; VHL: Von Hippel-Lindau 59 © Arcus Biosciences 2024

  60. Slide 60: Casdatifan in the Cancer Cell Nucleus

    Casdatifan (HIF-2a inhibitor) in the Cancer Cell Nucleus 1 In many cancers, the 3 Cas binds to HIF-2α transcription factor HIF-2α is dysregulated, allowing it to casdatifan The highly specific small molecule cas can translocate freely to the penetrate cells and bind cancer cell nucleus. HIF-2α. HIF-

  61. Slide 61: CD73-Adenosine Axis Role in Immune Suppression

    The CD73-Adenosine Axis Plays a Well-Established and Critical Role in Suppression of the Immune Response NK Cells ATP ↓ cytotoxicity etrumadenant blocks adenosine from binding to A2aR and A2bR, 1 ATP is released from blocking immunosuppression A2a tumor cells in A2b Receptor response to cellular Rec

  62. Slide 62: Platform Design to Evaluate Novel Combinations for NSCLC

    Platform Design to Rapidly Evaluate Novel Combinations for NSCLC, Including Quemli and Dom-based Regimens PRELIMINARY STAGE EXPANSION PRE-SCREENING SCREENING (N=20/30) STAGE PRIMARY ENDPOINTS • ORR • Safety and tolerability EXPERIMENTAL SUB-STUDY A TREATMENT ARMS Treatment arm(s) SECONDARY 1L, metas

  63. Slide 63: Combining to Cure

    RCUS BIOSCIENCES COMBINING TO CURE”

Arcus Biosciences — Q4 2023 Earnings Presentation on 6ix